Home > Resources > Whitepapers > Trends in the Biosimilars Market

Trends in the Biosimilars Market

May 17, 2018

Despite biosimilars being available for over ten years in some markets, the biosimilars market continues to evolve. Development of biosimilars is a truly global endeavour, helped by the spread of regulatory guidance. In this white paper, we explore the biosimilar R&D landscape, physician attitudes towards biosimilars, and drivers to prescribe, as well as two case studies on the launch dynamics of Sandoz’s Zarxio and Pfizer’s Inflectra in the United States.

Spotlight

9D Home Care Pty Ltd

9D Homecare is a registered NDIS Service Provided based in Melbourne specialising in providing a discreet quality but full fledge range of Residential and Home Care for all purpose service in accordance with individual demands and necessities.

OTHER WHITEPAPERS

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Asia Pacific – Clinical trial landscape

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

Benefit-Risk Considerations for Product Quality Assessments; Guidance for Industry; DRAFT GUIDANCE

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section

Risk assessment of fungal materials

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

A New Generation of Cancer Immunotherapies

whitePaper | June 9, 2022

Despite recent progress in fighting cancer the sad reality is that it remains a leading cause of morbidity and mortality. Some of the most promising new treatments have emerged from the convergence of the oncology and immunology fields.

A Playbook for Emerging Biotechs

whitePaper | March 24, 2023

The global biotech industry continues to witness growth with an estimated market size of nearly $300B, despite the current state of the funding environment